Brainvectis received the Orphan Drug Designation (ODD) from the European Commission for BV-CYP01, its gene therapy drug candidate for the treatment of Huntington’s disease.
[…] lead gene therapy candidate has shown proof-of-concept in animal models of Huntington’s. It also received orphan drug designation from the European Commission last […]
[…] lead gene therapy candidate has shown proof-of-concept in animal models of Huntington’s. It also received orphan drug designation from the European Commission last […]
×
[…] lead gene therapy candidate has shown proof-of-concept in animal models of Huntington’s. It also received orphan drug designation from the European Commission last […]
[…] lead gene therapy candidate has shown proof-of-concept in animal models of Huntington’s. It also received orphan drug designation from the European Commission last […]